

Stuart L Goldberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5265604/publications.pdf>

Version: 2024-02-01

73
papers

1,564
citations

567281

15
h-index

315739

38
g-index

76
all docs

76
docs citations

76
times ranked

2913
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075. | 10.7 | 402 |
| 2 | Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. <i>Lancet Rheumatology</i> , The, 2020, 2, e603-e612. | 3.9 | 228 |
| 3 | Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. <i>Blood</i> , 2002, 99, 1486-1488. | 1.4 | 180 |
| 4 | Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML. <i>Blood</i> , 2018, 132, 598-607. | 1.4 | 128 |
| 5 | Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. <i>Current Medical Research and Opinion</i> , 2013, 29, 1075-1082. | 1.9 | 49 |
| 6 | The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1211-1216. | 2.0 | 47 |
| 7 | Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. <i>Current Medical Research and Opinion</i> , 2014, 30, 1345-1352. | 1.9 | 41 |
| 8 | First–line treatment selection and early monitoring patterns in chronic phase–chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2017, 92, 1214-1223. | 4.1 | 36 |
| 9 | Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic–phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2019, 94, 46-54. | 4.1 | 32 |
| 10 | Barriers to Physician Adherence to Evidence-Based Monitoring Guidelines in Chronic Myelogenous Leukemia. <i>Journal of Oncology Practice</i> , 2015, 11, e398-e404. | 2.5 | 29 |
| 11 | Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. <i>JCI Insight</i> , 2021, 6, . | 5.0 | 29 |
| 12 | Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies. <i>Supportive Care in Cancer</i> , 2004, 12, 526-30. | 2.2 | 24 |
| 13 | Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9. | 3.0 | 20 |
| 14 | Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. <i>Blood</i> , 2015, 126, 321-321. | 1.4 | 19 |
| 15 | A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2007, 110, 2569-2569. | 1.4 | 18 |
| 16 | Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, S16-S22. | 0.8 | 16 |
| 17 | Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 711-714. | 0.4 | 15 |
| 18 | Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic–phase CML in clinical practice: 3–year European SIMPLICITY data. <i>European Journal of Haematology</i> , 2021, 106, 82-89. | 2.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias. <i>Blood</i> , 2019, 134, 3812-3812. | 1.4 | 13 |
| 20 | Differential impact of cognitive computing augmented by real world evidence on novice and expert oncologists. <i>Cancer Medicine</i> , 2019, 8, 6578-6584. | 2.8 | 12 |
| 21 | Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.. <i>Blood</i> , 2009, 114, 2089-2089. | 1.4 | 12 |
| 22 | Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 341-349.e1. | 0.4 | 11 |
| 23 | Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 2384-2393. | 1.3 | 11 |
| 24 | A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509. | 4.1 | 11 |
| 25 | Clinical and Economic Consequences of Myelodysplastic Syndromes in the United States: An Analysis of the Medicare Database. <i>Blood</i> , 2008, 112, 636-636. | 1.4 | 9 |
| 26 | Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 98-105. | 0.4 | 8 |
| 27 | A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results. <i>Blood</i> , 2008, 112, 5084-5084. | 1.4 | 8 |
| 28 | A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to 2 BCR-ABL Tyrosine Kinase Inhibitors. <i>Blood</i> , 2008, 112, 4254-4254. | 1.4 | 7 |
| 29 | Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Blood</i> , 2008, 112, 3651-3651. | 1.4 | 6 |
| 30 | Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. <i>Blood</i> , 2017, 130, 891-891. | 1.4 | 6 |
| 31 | Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. <i>Leukemia and Lymphoma</i> , 2018, 59, 2135-2143. | 1.3 | 5 |
| 32 | Development of a Precise, Clinically Relevant, Digital Classification Schema for Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-10. | 2.1 | 5 |
| 33 | Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2008, 112, 3051-3051. | 1.4 | 5 |
| 34 | Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. <i>Journal of Clinical Oncology</i> , 2020, 38, 1367-1368. | 1.6 | 4 |
| 35 | Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431. | 4.1 | 4 |
| 36 | Predictors of performing response monitoring in patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY).. <i>Journal of Clinical Oncology</i> , 2014, 32, 116-116. | 1.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Real-world economic value of a 21-gene assay in early-stage breast cancer. American Journal of Managed Care, 2017, 23, e416-e420. | 1.1 | 4 |
| 38 | Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 213-219.e4. | 0.4 | 3 |
| 39 | Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients. Blood, 2019, 134, 4576-4576. | 1.4 | 3 |
| 40 | Myelodysplastic Syndrome Patients Obtaining a Cytogenetic Response to Outpatient Decitabine Experience Improved Hematological Responses and Longer Survival: Additional Analyses From the ADOPT Trial. Blood, 2009, 114, 3817-3817. | 1.4 | 3 |
| 41 | Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma. Blood, 2019, 134, 3141-3141. | 1.4 | 2 |
| 42 | Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS). Blood, 2006, 108, 2657-2657. | 1.4 | 2 |
| 43 | A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR. Blood, 2015, 126, 5168-5168. | 1.4 | 2 |
| 44 | Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice. Blood, 2016, 128, 937-937. | 1.4 | 2 |
| 45 | Interim Analysis of a Multicenter Trial of High Dose (HD) Imatinib in Newly Diagnosed Early Chronic Phase (CP) Patients (pt) with Chronic Myeloid Leukemia (CML). Blood, 2005, 106, 1085-1085. | 1.4 | 2 |
| 46 | Treatment of T Cell Large Granular Lymphocyte Leukemia with Reduced-Intensity Allogeneic Stem Cell Transplantation. Blood, 2007, 110, 4931-4931. | 1.4 | 2 |
| 47 | Risk Adapted Dose Intensive DICEP Salvage Chemotherapy Prior to Autologous Stem Cell Transplantation Yields Successful Outcomes in Chemotherapy Refractory Lymphoma. Blood, 2004, 104, 898-898. | 1.4 | 1 |
| 48 | Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib. Blood, 2009, 114, 2206-2206. | 1.4 | 1 |
| 49 | Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR4.5) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENEStnext Study Update. Blood, 2013, 122, 4015-4015. | 1.4 | 1 |
| 50 | Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL). Blood, 2016, 128, 2973-2973. | 1.4 | 1 |
| 51 | Guillain-Barre Syndrome Complicating Multiple Myeloma. Blood, 2008, 112, 5135-5135. | 1.4 | 1 |
| 52 | Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study. Blood, 2009, 114, 1214-1214. | 1.4 | 1 |
| 53 | Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation. Blood, 2019, 134, 3316-3316. | 1.4 | 1 |
| 54 | Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2019, 134, 5510-5510. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Autologous Peripheral Blood Stem Cell Transplant for Relapsed or Refractory T-Cell Non-Hodgkinâ€™s Lymphoma Results in Inferior Long Term Survival when Compared to Relapsed or Refractory B-Cell Non-Hodgkinâ€™s Lymphomas.. Blood, 2004, 104, 5241-5241. | 1.4 | 0 |
| 56 | A Myeloablative Conditioning Regimen Is Required to Produce Durable Engraftment and Immune Reconstitution in Related and Unrelated Multi-Antigen HLA Mismatched Pan-T-Cell Depleted Limited T-Cell Add-Back Transplants.. Blood, 2004, 104, 5185-5185. | 1.4 | 0 |
| 57 | Comprehensive Immune Reconstitution without Development of Graft Versus Host Disease (GvHD) Using Limited T-Cell Add Back at the Time of Unrelated Multi-Antigen Mismatched Pan-T-Cell Depleted Transplant.. Blood, 2005, 106, 5383-5383. | 1.4 | 0 |
| 58 | 5-Azacitidine Therapy in Elderly Patients with Acute Myelogenous Leukemia Yields Similar Survival Compared to 3+7 Induction Chemotherapy with Less Transfusional Support, Bacteremias, and Hospital Days.. Blood, 2006, 108, 4569-4569. | 1.4 | 0 |
| 59 | Long-Term Survival of Patients with Myelofibrosis Treated with Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2704-2704. | 1.4 | 0 |
| 60 | Cryopreservation of Peripheral Blood Stem Cells (PBSC) with Hydroxyethylstarch (HES) and Dimethylsulfoxide (DMSO) Results in Faster Granulocyte Recovery Than Using Dimethylsulfoxide Alone.. Blood, 2007, 110, 3287-3287. | 1.4 | 0 |
| 61 | DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma.. Blood, 2007, 110, 3284-3284. | 1.4 | 0 |
| 62 | Outcome of Patients with Myeloproliferative Disorders Treated with Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2008, 112, 2797-2797. | 1.4 | 0 |
| 63 | Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CPCML).. Blood, 2008, 112, 2128-2128. | 1.4 | 0 |
| 64 | Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).. Journal of Clinical Oncology, 2016, 34, 7014-7014. | 1.6 | 0 |
| 65 | Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).. Journal of Clinical Oncology, 2016, 34, 7061-7061. | 1.6 | 0 |
| 66 | Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Meta-Analysis of Randomized Controlled Trials. Blood, 2016, 128, 5596-5596. | 1.4 | 0 |
| 67 | The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients. Blood, 2018, 132, 5600-5600. | 1.4 | 0 |
| 68 | Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey. Blood, 2018, 132, 5843-5843. | 1.4 | 0 |
| 69 | Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice. Blood, 2018, 132, 1730-1730. | 1.4 | 0 |
| 70 | Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma. Blood, 2019, 134, 2193-2193. | 1.4 | 0 |
| 71 | Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC). Blood, 2019, 134, 4475-4475. | 1.4 | 0 |
| 72 | Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). Blood, 2019, 134, 2929-2929. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice. <i>Blood</i> , 2019, 134, 4151-4151. | 1.4 | 0 |